# ​Temporal proteomic profiling of iPSC-derived human liver organoids reveals optimal maturation for drug metabolism and toxicology

## TL;DR

This study tracks protein changes in lab-grown liver organoids over time to find the best stage for drug testing and toxicity studies.

## Contribution

The study identifies Day 30 as the optimal maturation stage for drug metabolism in iPSC-derived liver organoids using proteomic profiling.

## Key findings

- Day 30 organoids show peak expression of drug-metabolizing enzymes like CYP3A4.
- Day 45 organoids shift toward a mesenchymal profile, useful for disease modeling.
- CYP3A4 activity in Day 30 organoids matches that of existing liver models like HepaRG cells.

## Abstract

Liver organoids have emerged as an innovative three-dimensional model system that effectively recapitulates the structural and functional complexities of human liver tissue, addressing limitations of traditional two-dimensional culture systems. This study presents a comprehensive temporal proteomic characterization of iPSC-derived human liver organoids (iHLOs) by profiling 5,736 proteins across their four developmental stages, Days 7, 15, 30, and 45, to identify optimal timepoints for drug metabolism and toxicological applications. The analysis revealed that Day 30 represents the peak of functional maturity, marked by the highest expression of key-metabolizing enzymes, such as cytochrome P450 3A4 (CYP3A4), along with cholangiocyte-specific proteins and hepatic metabolic enzymes. Functional validation of CYP3A4 activity through rifampicin induction and ketoconazole inhibition demonstrated metabolic competence comparable to existing in vitro liver models, including HepaRG cells and primary human hepatocytes. Interestingly, Day 45 organoids exhibited a shift toward a mesenchymal cell profile, with increased markers of hepatic stellate cells, suggesting utility for disease modeling applications. These findings indicate Day 30 of liver organoids as the optimal stage for drug metabolism and toxicological investigations, providing a proteomic framework that enhances their utility of iHLOs as physiologically relevant liver models.

The online version contains supplementary material available at 10.1038/s41598-025-32539-0.